GE HealthCare and University Hospital Essen Collaborate to Advance Theranostics and Personalized Cancer Care with New Nuclear Medicine Center

• World‑first installation of GE HealthCare’s StarGuide™ GX SPECT/CT, alongside one of the first Omni ™ 128 cm PET/CT systems, advancing highly sensitive whole‑body imaging for oncology.
• A fully integrated, end-to-end design connects the entire theranostics care pathway - from tracer production to AI-enabled image analysis and post-processing, further enabling seamless collaboration to advance disease treatment.
• The center aims for faster, more precise and personalized cancer care through seamless collaboration across disciplines and advanced molecular imaging technologies.

Essen, Germany - June 30, 2026 - GE HealthCare (Nasdaq: GEHC) today highlighted its collaboration with University Hospital Essen as the hospital officially opens a new state‑of‑the‑art Nuclear Medicine Center.
The center marks an important milestone in advancing theranostics - the combination of diagnostics and therapy - and accelerating the adoption of more personalized approaches to cancer care in Europe.

Theranostics is helping to transform cancer care by enabling clinicians to evaluate, even before treatment begins, whether a therapy is likely to be effective. This more informed approach can help reduce uncertainty and enable highly targeted, individualized care. The new facility in Essen brings this approach to life through advanced imaging technologies, including the world’s first installation of GE HealthCare’s StarGuide™ GX SPECT/CT^[i] and the addition of Omni™ 128 cm PET/CT.^[ii] Together, these systems enable highly sensitive, whole-body imaging and support fast, precise clinical decision-making across a wide range of oncology applications.

A defining feature of the center is its fully integrated, end-to-end design. By combining radiopharmaceutical capabilities, advanced imaging, and MIM software, it connects the entire theranostics pathway - from tracer production to AI‑enabled image analysis and post-processing. Bringing these capabilities together within a single site enables seamless collaboration across disciplines, helping clinicians visualize disease, track progression, and tailor treatment strategies with confidence.

“The opening of this new center reflects our shared commitment to pushing the boundaries of molecular imaging and theranostics,” said Christian Bernhard, International Enterprise Solutions General Manager at GE HealthCare “University Hospital Essen is an outstanding collaborator, not only for its clinical leadership but for its focus on what matters most - patients. Together, we are enabling more precise and timely insights, short and comfortable exams, and personalized treatment decisions, ultimately helping patients get the answers and care they need fast.”

The center is designed to support a broad range of clinical applications, particularly in oncology, further strengthening Essen’s position as a leading European hub for molecular imaging and theranostics.

The official opening on June 30 brought together around 300 representatives from government, healthcare, and academia, underscoring the strategic importance of innovation and collaboration in strengthening healthcare systems and expanding access to advanced cancer care.
“Nuclear Medicine and Theranostics are undergoing transformative changes. A once in a lifetime opportunity for our field. To successfully capitalize on these opportunities and challenges it requires to have an excellent, committed and reliable partner which we found in GE HealthCare. Now it is time to jointly deliver,” added Prof. Ken Herrmann, Chair, Department of Nuclear Medicine, University Hospital Essen.

This milestone builds on the ongoing collaboration between GE HealthCare and University Hospital Essen to expand access to advanced molecular imaging and accelerate the adoption of theranostics across Europe.

[i] StarGuide GX is CE marked. Not approved or cleared by the U.S. FDA. Not available for sale in the United States and other countries.

[ii] Omni with 128cm AFOV is CE marked. Not approved or cleared by the U.S. FDA. Not available for sale in the United States and other countries.